Table 2 Effects of nonsynonymous BCL2 mutation on FL outcomes.

From: Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era

VAF ≥20%a

EFS

OS

Transformation

Lymphoma death

Non-lymphoma death

Treatment

N

Adjustment

EFS

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

All

199

None

1.29

0.88–1.91

0.19

1.82

1.05–3.17

0.034

1.15

0.51–2.60

0.73

1.41

0.67–2.95

0.37

2.31

0.89–6.02

0.087

All

199

FLIPI, Treatment

1.55

1.02–2.35

0.043

1.74

0.87–3.11

0.063

   

Non-systemic

97

None

1.91

0.99–3.67

0.052

2.14

0.87–5.29

0.10

3.01

1.04–8.78

0.043

1.38

0.29–6.53

0.69

2.44

0.65–9.13

0.18

Non-systemic

97

FLIPI

1.70

0.88–3.30

0.12

1.93

0.77–4.87

0.16

   

R-based

91

None

1.33

0.75–2.36

0.33

1.99

0.82–4.78

0.12

0.64

0.13–3.11

0.58

1.16

0.39–3.45

0.8

N/A (3 deaths)

R-based

91

FLIPI

1.29

0.72–2.29

0.73

1.96

0.81–4.72

0.13

   

VAF ≥5%b

EFS

OS

Transformation

Lymphoma death

Non-lymphoma death

Treatment

N

Adjustment

HR

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

All

199

None

1.15

0.80–1.65

0.44

1.63

0.96–2.78

0.073

1.03

0.48–2.19

0.94

1.07

0.52–2.20

0.85

2.54

0.99–6.53

0.053

All

199

FLIPI, Treatment

1.22

0.84–1.77

0.31

1.43

0.82–2.47

0.21

   

Non-systemic

97

None

1.26

0.74–2.12

0.40

1.82

0.84–3.95

0.13

1.56

0.58–4.18

0.38

1.01

0.37–3.78

0.99

2.31

0.74–7.25

0.15

Non-systemic

97

FLIPI

1.16

0.69–1.97

0.57

1.67

0.76–3.70

0.20

   

R-based

91

None

1.19

0.68–2.10

0.54

1.58

0.66–3.82

0.30

0.9

0.22–3.69

0.88

0.9

0.30–2.69

0.85

N/A (3 deaths)

R-based

91

FLIPI

1.11

0.63–1.98

0.72

1.23

0.51–2.99

0.64

   
  1. aValues indicate the relationship between indicated clinical outcome and presence vs. absence of a nonsynonymous BCL2 mutation at VAF ≥20%.
  2. bValues indicate the relationship between indicated clinical outcome and the presence vs. absence of a nonsynonymous BCL2 mutation at VAF ≥5%.